<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="jmv25961-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float">
 <label>Table 1</label>
 <caption>
  <p>The efficacy and safety of convalescent plasma transfusion (CPT) in patients with COVID‐19</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
  <thead valign="bottom">
   <tr style="border-bottom:solid 1px #000000" valign="bottom">
    <th valign="bottom" rowspan="1" colspan="1">Author</th>
    <th valign="bottom" rowspan="1" colspan="1">Country</th>
    <th valign="bottom" rowspan="1" colspan="1">Study period</th>
    <th valign="bottom" rowspan="1" colspan="1">Study population</th>
    <th valign="bottom" rowspan="1" colspan="1">CPT dosage</th>
    <th valign="bottom" rowspan="1" colspan="1">Antiviral (antimicrobial drugs)</th>
    <th valign="bottom" rowspan="1" colspan="1">Administrated day</th>
    <th valign="bottom" rowspan="1" colspan="1">Status during CPT</th>
    <th valign="bottom" rowspan="1" colspan="1">Outcome</th>
    <th valign="bottom" rowspan="1" colspan="1">Viral load</th>
    <th valign="bottom" rowspan="1" colspan="1">Severe adverse events &amp; treatment complications</th>
   </tr>
  </thead>
  <tbody valign="top">
   <tr>
    <td valign="top" rowspan="1" colspan="1">Duan et al
     <xref rid="jmv25961-bib-0006" ref-type="ref">
      <sup>6</sup>
     </xref>
    </td>
    <td valign="top" rowspan="1" colspan="1">China</td>
    <td valign="top" rowspan="1" colspan="1">23 January 2020 to 19 February 2020</td>
    <td valign="top" rowspan="1" colspan="1">10, 6 M:4 F, Age (x̃‐52.5 y), Cardiovascular and/or cerebrovascular diseases and HTN (n = 4)</td>
    <td valign="top" rowspan="1" colspan="1">200 mL within 4 h, antibody titer &gt;1:640</td>
    <td valign="top" rowspan="1" colspan="1">
     <p>arbidol or/and remdesivir/ribavirin/peramivir (n = 9)</p>
     <p>ribavirin (n = 1)</p>
     <p>Antibacterial/antifungal for coninfecion (n = 8)</p>
    </td>
    <td valign="top" rowspan="1" colspan="1">Onset to CPT (x̃ ‐16.5 d)</td>
    <td valign="top" rowspan="1" colspan="1">All at ICU, Mechanical ventilation (n = 3), HFNO (n = 3), Conventional LFNO (n = 2)</td>
    <td valign="top" rowspan="1" colspan="1">
     <p>Clinical symptoms, paraclinical improved,</p>
     <p>Increase of oxyhemoglobin saturation within 3 d</p>
     <p>CP well tolerated, increase/maintain the neutralizing antibodies,</p>
     <p>Varying degrees of absorption of lung lesions within 7 d</p>
    </td>
    <td valign="top" rowspan="1" colspan="1">Viral load undetectable (n = 7), Neutralizing antibody increased rapidly up to 1:640 (n = 5), maintained at a high level (1:640) (n = 4)</td>
    <td valign="top" rowspan="1" colspan="1">No severe adverse effects, Evanescent facial red spot (n = 1)</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Chenguang Shen et al
     <xref rid="jmv25961-bib-0007" ref-type="ref">
      <sup>7</sup>
     </xref>
    </td>
    <td valign="top" rowspan="1" colspan="1">China</td>
    <td valign="top" rowspan="1" colspan="1">20 January 2020 to 25 March 2020</td>
    <td valign="top" rowspan="1" colspan="1">5, Age (range, 36‐73 y), 3M:2F, HTN; mitral insufficiency (n=1)</td>
    <td valign="top" rowspan="1" colspan="1">400 mL of CP in 2 doses on the same day, antibody titer &gt;1:1000</td>
    <td valign="top" rowspan="1" colspan="1">interferon alfa‐1b + Lopinavir/ritonavir (n = 4) + favipiravir (n = 1), arbidol + darunavir + Lopinavir/ritonavir (n=1)</td>
    <td valign="top" rowspan="1" colspan="1">After admission between 10 and 22 d</td>
    <td valign="top" rowspan="1" colspan="1">All 5 critical severe ARDS on mechanical ventilation, ECMO (n = 1)</td>
    <td valign="top" rowspan="1" colspan="1">Temp normalized within 3 d (n = 4), SOFA score decreased, and PAO2/FIO2 increased within 12 d (range, 172‐276 before and 284‐366 after), Neutralizing antibody titers increased (range, 40‐60 before and 80‐320 on 7th d), ARDS resolved (n = 4) at 12 d, Weaned from mechanical ventilation (n = 3) within 2 wk</td>
    <td valign="top" rowspan="1" colspan="1">Decreased and became negative within 12 d</td>
    <td valign="top" rowspan="1" colspan="1">No severe adverse effects</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Bin Zhang et al
     <xref rid="jmv25961-bib-0008" ref-type="ref">
      <sup>8</sup>
     </xref>
    </td>
    <td valign="top" rowspan="1" colspan="1">China</td>
    <td valign="top" rowspan="1" colspan="1">16 February 2020 to 15 March 2020</td>
    <td valign="top" rowspan="1" colspan="1">69 y/F, HTN</td>
    <td valign="top" rowspan="1" colspan="1">900 mL in 3 doses</td>
    <td valign="top" rowspan="1" colspan="1">arbidol, lopinavir‐ritonavir, interferon alpha</td>
    <td valign="top" rowspan="1" colspan="1">After admission 19th d</td>
    <td valign="top" rowspan="1" colspan="1">Critically ill invasive mechanical ventilation</td>
    <td valign="top" rowspan="1" colspan="1">Extubated and non‐invasion ventilation was given on 34th d, Chest CT persistent absorption of consolidation, discharged on 44th d</td>
    <td valign="top" rowspan="1" colspan="1">Decreased 55 × 10
     <sup>5</sup> copies/mL (20th d) ‐ 3.9 × 10
     <sup>4</sup> copies/mL (30th d) ‐ 180 copies/mL (36th d). Negative (40th, 42th d)
    </td>
    <td valign="top" rowspan="1" colspan="1">No severe adverse effects</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">55 y/M, COPD</td>
    <td valign="top" rowspan="1" colspan="1">200 mL</td>
    <td valign="top" rowspan="1" colspan="1">arbidol, lopinavir‐ritonavir, interferon alpha‐2b</td>
    <td valign="top" rowspan="1" colspan="1">After admission 12th d</td>
    <td valign="top" rowspan="1" colspan="1">Critically ill ARDS invasive mechanical ventilation</td>
    <td valign="top" rowspan="1" colspan="1">pO2 increased to 97 mm Hg with OI of 198 mm Hg in 1 d, All drugs discontinued except methylprednisolone, Chest images absorption of interstitial pneumonia (13th d‐17th d), Discharged on (19th d)</td>
    <td valign="top" rowspan="1" colspan="1">Negative (18th d)</td>
    <td valign="top" rowspan="1" colspan="1">No adverse reactions</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">73 y/M, HTN &amp; chronic renal f‐ure</td>
    <td valign="top" rowspan="1" colspan="1">2400 mL in 8 doses</td>
    <td valign="top" rowspan="1" colspan="1">arbidol, lopinavir‐ritonavir, oseltamivir, ribavirin, interferon alpha‐2b</td>
    <td valign="top" rowspan="1" colspan="1">After admission 15th d</td>
    <td valign="top" rowspan="1" colspan="1">Critically ill Acute respiratory failure invasive mechanical ventilation in V‐V ECMO</td>
    <td valign="top" rowspan="1" colspan="1">Positive anti‐SARS‐CoV‐2 IgG (26th d). Chest x‐rays absorbed infiltrative lesions but pneumothorax, Serum IgM level decreased to normal range (45th d, 46th d), Transferred to unfenced ICU for underlying diseases, multiple organ failure (50th d)</td>
    <td valign="top" rowspan="1" colspan="1">Negative (45th d, 46th d)</td>
    <td valign="top" rowspan="1" colspan="1">No adverse reactions</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">31 y/F, pregnant (35 wk &amp; 2 d)</td>
    <td valign="top" rowspan="1" colspan="1">300 mL</td>
    <td valign="top" rowspan="1" colspan="1">lopinavir‐ritonavir and ribavirin, Imipenem, vancomycin for coinfection</td>
    <td valign="top" rowspan="1" colspan="1">After admission 19th d</td>
    <td valign="top" rowspan="1" colspan="1">Critically ill ARDS, invasive mechanical ventilation in V‐V ECMO</td>
    <td valign="top" rowspan="1" colspan="1">Removed CRRT, ECMO (27th d), anti‐SARS‐CoV‐2 IgM changed from positive to weakly positive to negative, anti‐SARS‐CoV‐2 IgG was persistently positive (35th d 37th d), Chest CT showed near‐complete absorption of opacities, Trachea cannula removed, nasal oxygen given (40th d), Discharged (46th d)</td>
    <td valign="top" rowspan="1" colspan="1">Negative (40th d, 43th d)</td>
    <td valign="top" rowspan="1" colspan="1">No adverse reactions</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Jin Young Ahn et al
     <xref rid="jmv25961-bib-0009" ref-type="ref">
      <sup>9</sup>
     </xref>
    </td>
    <td valign="top" rowspan="1" colspan="1">South Korea</td>
    <td valign="top" rowspan="1" colspan="1">22 February 2020 to 6 March 2020</td>
    <td valign="top" rowspan="1" colspan="1">71 y/M</td>
    <td valign="top" rowspan="1" colspan="1">500 mL in 2 doses at 12 h interval</td>
    <td valign="top" rowspan="1" colspan="1">hydroxychloroquine, lopinavir/ritonavir</td>
    <td valign="top" rowspan="1" colspan="1">After admission 10th d</td>
    <td valign="top" rowspan="1" colspan="1">Severe ARDS, mechanical ventilation</td>
    <td valign="top" rowspan="1" colspan="1">Weaned from the mechanical ventilator, underwent a tracheostomy</td>
    <td valign="top" rowspan="1" colspan="1">Ct changed 24.98 (10th d) ‐ 33.96 (20th d), Negative (after 26th d)</td>
    <td valign="top" rowspan="1" colspan="1">No adverse reaction</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">67 y/F, HTN</td>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">After admission 6th d</td>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">Extubated and discharged on 24th d</td>
    <td valign="top" rowspan="1" colspan="1">Negative (after 20th d). Ct changed 20.51 (5th d) ‐36.33 (9th d)</td>
    <td valign="top" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1">Mingxiang Ye et al
     <xref rid="jmv25961-bib-0010" ref-type="ref">
      <sup>10</sup>
     </xref>
    </td>
    <td valign="top" rowspan="1" colspan="1">China</td>
    <td valign="top" rowspan="1" colspan="1">11 February 2020 to 18 March 2020</td>
    <td valign="top" rowspan="1" colspan="1">69/M</td>
    <td valign="top" rowspan="1" colspan="1">600 mL in 3 doses</td>
    <td valign="top" rowspan="1" colspan="1">arbidol, levofloxacin</td>
    <td valign="top" rowspan="1" colspan="1">After symptom 33th d</td>
    <td valign="top" rowspan="1" colspan="1">Myalgia, Chest CT‐patchy areas of GGOs</td>
    <td valign="top" rowspan="1" colspan="1">Symptoms improved, GGOs resolved 37th d, Cured and ready to discharge.</td>
    <td valign="top" rowspan="1" colspan="1">Negative</td>
    <td valign="top" rowspan="1" colspan="1">No adverse reaction</td>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">75/F</td>
    <td valign="top" rowspan="1" colspan="1">400 mL in 2 doses</td>
    <td valign="top" rowspan="1" colspan="1">arbidol</td>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">Fatigue, shortness of breath, oxygen therapy through nasal catheter, respiratory distress, Multiple consolidation</td>
    <td valign="top" rowspan="1" colspan="1">Symptoms improved, alleviation of respiratory distress, two‐fold increase in IgM and IgG titers, consolidation gradually reduced, turned into scattered GGOs, Cured and under further clinical monitoring</td>
    <td valign="top" rowspan="1" colspan="1">Negative</td>
    <td valign="top" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">56/M, Bronchitis</td>
    <td valign="top" rowspan="1" colspan="1">600 mL in 3 doses</td>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">Fever, nonproductive cough, shortness of breath, Chest CT‐Multiple GGOs, reticular opacities, and fibrosis streak,</td>
    <td valign="top" rowspan="1" colspan="1">Symptoms improved, complete resolution consolidation,gradually resolution of GGOs, IgM and IgG titers increased Discharged</td>
    <td valign="top" rowspan="1" colspan="1">Not mentioned</td>
    <td valign="top" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">63/F Sjogren syndrome</td>
    <td valign="top" rowspan="1" colspan="1">200 mL</td>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">After symptom 40th d</td>
    <td valign="top" rowspan="1" colspan="1">Fever, cough, shortness of breath, decreased exercise tolerance, Chest CT ‐Multiple GGOs with consolidation and fibrosis streak</td>
    <td valign="top" rowspan="1" colspan="1">Symptoms improved, GGOs tended to reduce, anti‐SARS‐CoV‐2 IgM and IgG, Discharged 46th d</td>
    <td valign="top" rowspan="1" colspan="1">Negative 41th d</td>
    <td valign="top" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">28/F</td>
    <td valign="top" rowspan="1" colspan="1">200 mL</td>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">After symptom 33th d</td>
    <td valign="top" rowspan="1" colspan="1">Fatigue and myalgia, other symptoms</td>
    <td valign="top" rowspan="1" colspan="1">Discharged 39th d</td>
    <td valign="top" rowspan="1" colspan="1">Negative</td>
    <td valign="top" rowspan="1" colspan="1"/>
   </tr>
   <tr>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">57/M</td>
    <td valign="top" rowspan="1" colspan="1">200 mL</td>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1">After symptom 50th d</td>
    <td valign="top" rowspan="1" colspan="1">Fever, cough, shortness of breath and myalgia, Chest CT‐ Extensive bilateral GGOs, respiratory distress</td>
    <td valign="top" rowspan="1" colspan="1">Symptoms improved, GGOs resolved, discharged 54th d</td>
    <td valign="top" rowspan="1" colspan="1"/>
    <td valign="top" rowspan="1" colspan="1"/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="jmv25961-tbl1-note-0001">
   <p>Abbreviations: ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; COVID‐19, coronavirus disease 2019; CP, convalescent plasma; CT, computed tomography; Ct, computed tomography; ECMO, extracorporeal membrane oxygenation; GGOs, ground‐glass opacity; HFNO, High‐flow nasal oxygen therapy; HFNC, high‐flow nasal cannula oxygenation; HTN, hypertension; ICU, Intensive care unit; IgG, immunoglobulin G; IgM, immunoglobulin M; LFNO, low‐flow nasal cannula oxygenation; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; SOFA, sequential organ failure assessment.</p>
  </fn>
 </table-wrap-foot>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
  <license>
   <license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
  </license>
 </permissions>
</table-wrap>
